JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on October 20, 2006
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
281/42/31212    most recent
M602445200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shanmugam, N.
Right arrow Articles by Natarajan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shanmugam, N.
Right arrow Articles by Natarajan, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Papers In Press, published online ahead of print August 24, 2006
J. Biol. Chem, 10.1074/jbc.M602445200
Submitted on March 15, 2006
Revised on August 23, 2006
Accepted on August 24, 2006

Interferon-gamma -inducible protein-10 mRNA stabilized by RNA binding proteins in monocytes treated with S100b

Narkunaraja Shanmugam, Richard M. Ransohoff, and Rama Natarajan

Gonda Diabetes Center, Beckman Research Institute of the City of Hope, Duarte, CA 91010

Corresponding Author: rnatarajan{at}coh.org

Chemokines mediate the recruitment and activation of blood monocyte/macrophages and lymphocytes to sites of inflammation. Expression of the chemokine Interferon-gamma -inducible protein (IP-10) has been documented in several inflammatory and autoimmune disorders including Type-1 diabetes. However, the mechanism of its expression in monocytes or functional role in diabetes is not known. Advanced glycation end products (AGEs) acting via their receptor, RAGE, play major roles in diabetic complications. In this study, we observed for the first time that S100b, an inflammatory protein as well as a specific RAGE ligand, significantly increased IP-10 mRNA and protein levels in THP-1 monocytes as well as peripheral blood monocytes. Promoter luciferase assays showed that IP-10 mRNA accumulation by S100b was not via increased transcription. On the other hand, S100b significantly increased IP-10 mRNA half-life and stability. This appeared to be mediated by S100b-induced binding of specific RNA binding protein(s) to a 3’UTR responsive region of the IP-10 mRNA. Our results demonstrate for the first time that diabetic stimuli such as RAGE ligands can induce inflammatory gene expression in monocytes via increased message stability.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
N. Shanmugam, J. L. Figarola, Y. Li, P. M. Swiderski, S. Rahbar, and R. Natarajan
Proinflammatory Effects of Advanced Lipoxidation End Products in Monocytes
Diabetes, April 1, 2008; 57(4): 879 - 888.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. L. Figarola, N. Shanmugam, R. Natarajan, and S. Rahbar
Anti-Inflammatory Effects of the Advanced Glycation End Product Inhibitor LR-90 in Human Monocytes
Diabetes, March 1, 2007; 56(3): 647 - 655.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.